Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery

I read with interest the article of Dr Sabzi and colleagues entitled “Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery” in this journal.[1] In this clinical trial study the authors have enrolled about 650 patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB). Low dose aprotinin (2 million kallikrein inactivation units (KIU) during initiation of CPB) had been given to 273 patients in aprotinin group. The authors have found decreased rate of blood product transfusions but increased rate of morbidity in this group.